SGEN Seagen Inc.

Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company markets ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of metastatic urothelial cancers; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. It also develops Tisotumab Vedotin for metastatic cervical cancer and other solid tumors; ladiratuzumab vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; and SEA-CD40, SEA-TGT, SEA-BCMA, and SEA-CD70 for various cancer diseases. Seagen Inc. has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and SpringWorks Therapeutics, Inc. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.

Date	Price Target	Rating	Analyst
2/16/2023	$140.00 → $175.00	In-line → Outperform	Evercore ISI
2/16/2023	$155.00 → $175.00	Outperform → Strong Buy	Raymond James
2/6/2023	$162.00 → $141.00	Outperform → Market Perform	SVB Securities
11/21/2022	$135.00	Hold	Truist
10/11/2022	$177.00 → $178.00	Market Perform → Outperform	BMO Capital Markets
6/29/2022	$220.00	Outperform	Raymond James
6/24/2022	$169.00	Market Perform	BMO Capital Markets
2/16/2022	$201.00 → $142.00	Market Outperform	JMP Securities
2/10/2022	$165.00 → $150.00	Neutral	Piper Sandler
2/10/2022	$154.00 → $132.00	Sector Perform	RBC Capital Mkts

Seagen Inc.

Peers

Recent Analyst Ratings for Seagen Inc.

Seagen Inc. Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Baker Bros. Advisors Lp returned $10,248,908,740 worth of shares to the company (44,755,060 units at $229.00), closing all direct ownership in the company (SEC Form 4)

Himes Vaughn B returned $30,765,005 worth of shares to the company (134,345 units at $229.00), closing all direct ownership in the company (SEC Form 4)

Simonian Nancy A returned $14,370,437 worth of shares to the company (62,753 units at $229.00), closing all direct ownership in the company (SEC Form 4)

Simpson Todd E returned $21,363,868 worth of shares to the company (93,292 units at $229.00), closing all direct ownership in the company (SEC Form 4)

Love Ted W returned $974,395 worth of shares to the company (4,255 units at $229.00), closing all direct ownership in the company (SEC Form 4)

Swain Sandra M returned $178,162 worth of shares to the company (778 units at $229.00), closing all direct ownership in the company (SEC Form 4)

Liu Jean I returned $11,163,292 worth of shares to the company (48,748 units at $229.00), closing all direct ownership in the company (SEC Form 4)

Welch Daniel G returned $3,543,775 worth of shares to the company (15,475 units at $229.00), closing all direct ownership in the company (SEC Form 4)

Epstein David R returned $3,757,203 worth of shares to the company (16,407 units at $229.00), closing all direct ownership in the company (SEC Form 4)

Seth Alpna returned $2,966,237 worth of shares to the company (12,953 units at $229.00), closing all direct ownership in the company (SEC Form 4)